Physicians Prefer AI at Critical Decision Moments - Despite Trusting It Less

AI is the go-to resource for physicians making treatment decisions, even as trust remains a concern. For pharma, the strategic imperative is clear: ensure your brand shows up inside AI at that decisive moment.

In a Nutshell

• Adoption runs deepest among the hematologists and oncologists pharma cares about most. 87% of physicians now use AI for clinical research, and regular use peaks among early- and mid-career physicians (68% and 61%), the industry's core prescriber audience. Use is set to climb further next year.
• Med AI platforms are trusted less than other sources, but they're the primary tool at critical decision moments. Med AI platforms rank just sixth of thirteen sources for clinical-decision trust. Yet physicians name them their most preferred resource at the moments that shape treatment: comparing options and reviewing clinical trial data.
• Physicians have engineered new workflows around the trust gap. Early-career physicians front-load AI, then verify it (69% cross-reference other sources); mid-career physicians bring it in later to synthesize. Structured workflows let a less-trusted tool carry real weight.
• For brands, the question becomes: what’s your AI share of voice? When Med AI platforms shape decisions at the critical moment, what matters is whether your brand appears when physicians ask. Measuring your AI share of voice is step one.

Ask a physician which resource they trust most for a clinical decision, and AI doesn't crack the top five. Ask which one they prefer for researching treatment options, and it's number one. That gap, between what physicians trust and what they actually reach for, marks the most significant shift in clinical decision-making today.

An April ZoomRx survey of 70 practicing heme/oncs found that 87% now use a Med AI platform for clinical research. That adoption, corroborated by ZoomRx's passive digital behavior tracking, shows AI moving swiftly from curiosity to default tool. The more interesting story lies in where adoption runs deepest, and in the specific moments of the clinical research process that Med AI platforms now dominate.

Adoption is deepest where it matters most

Looking at adoption by career stage shows a more nuanced story. Across every tenure band, most physicians have now tried AI, but trial and habit are not the same, and that's where the divide appears. Regular use is high among early-career physicians (68%) and mid-career physicians (61%) but is lower among those later in their careers (44%). Furthermore, adoption is likely to continue deepening, with about four in five early- and mid-career physicians expecting to increase their AI use over the next year.

These early- and mid-career physicians are the core audience for pharma marketers. Understanding how AI shapes their clinical decisions is now essential.

Med AI platforms are the go-to resource in key decision moments

Across measures of trust and influence, Med AI platforms rank only as a second-tier resource. Yet physicians consistently prefer them in the moments that actually shape treatment decisions: comparing options and reviewing clinical trial data.

When comparing treatment options, Med AI platforms tie with clinical decision support tools like UpToDate as the most preferred resource (29% each), ahead of journals and every other source. When reviewing clinical trial data, they move into first outright, named the top choice by 31% of physicians versus 24% for clinical decision support.

The pattern intensifies inside pharma's key demographic: early- and mid-career physicians are nearly twice as likely to choose Med AI platforms over clinical decision support when comparing treatments or reviewing trial data.

Med AI platforms drive decisions for pharma's core audience exactly where it counts, even though physicians rate their output as less trustworthy than clinical decision support tools or journals. Which raises the obvious question: why do physicians lean on a tool you don't trust most?

Physicians have engineered their workflows to close the AI trust gap

The answer: physicians have engineered their workflows around AI, leaning on a tool they don't fully trust, with the approach shifting by career stage.

Early-career physicians front-load AI. 45% start their research with AI, using it for orientation and a fast first read, then verifying what it returns: 69% always or usually cross-reference against other sources. AI is the opening move; verification is the habit that follows.

Mid-career physicians work the other way. They're more likely to bring AI in later (28%, versus just 3% of early-career physicians), using it to synthesize and fill gaps rather than to orient. Because they're confirming rather than discovering, they verify somewhat less (56%).

Two approaches, one strategy: structure the workflow so a less-trusted tool still carries real weight. It shows how deeply Med AI platforms now sit inside the research process.

What this means for pharma brand teams

Med AI platforms are becoming part of the clinical workflow itself. They're the most preferred resource in the moments that decide treatment, and they're gaining ground among high-value prescribers who expect to use them more. The strategic question is no longer whether AI shapes treatment decisions. It's whether your brand shows up in the AI responses physicians rely on.

Marketers can't directly shape generative AI outputs, but they can measure their brand's presence within them. AI share of voice quantifies where, how often, and in what context brands appear in AI-generated responses. It's the first step toward generative engine optimization (GEO): marketers can't optimize what they can't see.

Physicians have already built AI into their most critical decisions. The only question left is which brands are present when they ask.

DATA SOURCE NOTE: ZoomRx DT HCP AI Browsing Journey Pulse Survey, April 2026. N=70 practicing physicians (under 11 years in practice, n=31; 11–20 years, n=23; 21+ years, n=16).